Nanoparticle comprising rapamycin and albumin as anticancer agent
AssigneeAbraxis BioScience, LLC
InventorsNeil P. Desai, Patrick Soon-Shiong, Vuong Trieu
Life of this patent
Estimating the term…
Abstract
The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Claims37
A method of treating cancer in a human individual, comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and albumin, wherein the rapamycin or derivative thereof is coated with albumin, wherein the amount of the rapamycin or derivative thereof in the effective amount of the composition is in the range of about 54 mg to about 180 mg, and wherein the average diameter of the nanoparticle in the capsule is no greater than about 200 nm.
A unit dosage form for treatment of cancer in a human individual comprising (a) nanoparticles that comprise rapamycin or a derivative thereof and albumin, wherein the rapamycin or derivative thereof is coated with albumin, wherein the amount of the rapamycin or derivative thereof in the unit dosage form is in the range of about 54 mg to about 180 mg, and (b) a pharmaceutically acceptable carrier, and wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
A kit comprising (a) nanoparticles that comprise rapamycin or a derivative thereof and albumin, wherein the rapamycin or derivative thereof is coated with albumin, wherein the amount of the rapamycin or derivative thereof in the kit is in the range of about 54 mg to about 180 mg, and (b) instructions for using the kit in treating cancer in a human individual, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
A method of treating cancer in a human individual comprising (a) a first therapy comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and albumin, where the rapamycin or derivative thereof is coated with albumin and (b) a second therapy selected from second therapy selected from the group consisting of chemotherapy, radiation therapy, surgery, hormone therapy, gene therapy, bone marrow transplantation, stem cell transplantation, targeted therapy, cryotherapy, ultrasound therapy, and immunotherapy, wherein the amount of the rapamycin or derivative thereof in the effective amount of the composition is in the range of about 54 mg to about 180 mg, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.
Dependencies are inferred from the claim text.